Avacta Group Plc (id:3596 AVCT)
49.50 GBP
Opening hours: 08:00 - 16:30 (GMT Standard Time: 12/24/2024 5:31:03 PM)
Exchange closed, opens in 14 hours 28 minutes
About Avacta Group Plc
Market Capitalization 163.01M
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
| Headquarters (address) |
Thorp Arch Estate Wetherby LS23 7FA United Kingdom |
| Phone | 44 1904 217 070 |
| Website | https://www.avacta.com |
| Employees | 154 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | AVCT |
| Exchange | London Stock Exchange |
| Currency | GBP |
| 52 week range | 39.50 - 119.90 |
| Market Capitalization | 163.01M |
| P/E trailing | -519.13 |
| P/E forward | 5.00 |
| Price/Sale | 7.21 |
| Price/Book | 324.07 |
| Beta | 1.18 |
| EPS | 5.00 |
| EPS United Kingdom (ID:3, base:630) | 3.00 |